A framework for assessing the impact of accelerated approval

The FDA’s Accelerated Approval program (AA) is a regulatory program to expedite availability of products to treat serious or life-threatening illnesses that lack effective treatment alternatives. Ideally, all of the many stakeholders such as patients, physicians, regulators, and health technology as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gould, A. Lawrence, Campbell, Robert K., Loewy, John W., Beckman, Robert A., Dey, Jyotirmoy, Schiel, Anja, Burman, Carl-Fredrik, Zhou, Joey, Antonijevic, Zoran, Miller, Eva R., Tang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231718/
https://www.ncbi.nlm.nih.gov/pubmed/35749431
http://dx.doi.org/10.1371/journal.pone.0265712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231718/
https://www.ncbi.nlm.nih.gov/pubmed/35749431
http://dx.doi.org/10.1371/journal.pone.0265712

Ejemplares similares